Catherine Elisabeth Charreyre

This inventor holds 18 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Vaccine Development. Top assignees: Merial Limited, Merial Sas, Boehringer Ingelheim Animal Health USA Inc.. Active years: 2002-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Catherine Elisabeth Charreyre. Retrieved from https://idiyas.com/inventor/catherine-elisabeth-charreyre

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 3)

% Patents Active = 88.9

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 1)

Average Co-Inventor Count = 6.0

ph-index = 11

Forward Citations = 753(Granted Patents)

Location History:

St.-Laurent De Mure, FR (2002)
Saint-Laurent de Mure, FR (2002 - 2010)
Lyons, FR (2017 - 2019)

Company Filing History:

Boehringer Ingelheim Animal Health USA Inc.

patents

4. 1 out of 13

Chulalongkorn University

patents

5. 4 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2019

Loading Chart...

Areas of Expertise:

Vaccine Formulations

Porcine Circovirus

Diagnostic Reagents

Recombinant Compositions

Needle-Free Administration

Viral Load Reduction

DNA Vaccine

PRRSV Vaccines

Myocarditis Prevention

Poxvirus Vaccine

Postweaning Wasting Syndrome

Intrauterine Infection

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10350287 - Hendra virus recombinant compositions and uses thereof (2019-07-16),

2. 9669085 - Needle-free administration of PRRSV vaccines (2017-06-06),

3. 7833783 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs (2010-11-16),

4. 7803926 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs (2010-09-28),

5. 7803613 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs (2010-09-28),

6. 7691368 - Vaccine formulations (2010-04-06),

7. 7608279 - Vaccine formulations (2009-10-27),

8. 7504206 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs (2009-03-17),

9. 7371395 - Vaccine formulations (2008-05-13),

10. 7211379 - Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 (2007-05-01),

11. 7192594 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs (2007-03-20),

12. 7122192 - Porcine circoviruses, vaccines and diagnostic reagents (2006-10-17),

13. 6943152 - DNA vaccine-PCV (2005-09-13),

14. 6660272 - Porcine circoviruses, vaccines and diagnostic reagents (2003-12-09),

15. 6517843 - Reduction of porcine circovirus-2 viral load with inactivated PCV-2 (2003-02-11),

Title: The Innovative Contributions of Catherine Elisabeth Charreyre

Introduction

Catherine Elisabeth Charreyre is a prominent inventor based in Saint-Laurent de Mure, France. She has made significant contributions to the field of biotechnology, particularly in vaccine development. With a total of 18 patents to her name, her work has had a substantial impact on public health.

Latest Patents

Among her latest patents is the invention related to Hendra virus recombinant compositions and their uses. This invention provides vectors that contain and express one or more Hendra virus polypeptides or antigens, which elicit an immune response in animals or humans against both Hendra virus and Nipah virus. The patent also includes methods of vaccination and kits for use with these compositions. Another notable patent is focused on needle-free administration of PRRSV vaccines. This invention outlines novel methods and compositions for vaccinating porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). It describes immunological compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which can be administered using needle-free delivery.

Career Highlights

Catherine has worked with notable companies in the biotechnology sector, including Merial Limited and Merial Sas. Her experience in these organizations has allowed her to develop innovative solutions that address critical health challenges.

Collaborations

Catherine has collaborated with esteemed colleagues such as Brian Martin Meehan and Edward Clark. These partnerships have further enhanced her research and development efforts in the field.

Conclusion

Catherine Elisabeth Charreyre's contributions to vaccine development and biotechnology are noteworthy. Her innovative patents and collaborations reflect her commitment to advancing public health through scientific research.

Profile summary based on public USPTO records.